Alzheimer's disease

Purpose of Study:  To evaluate the effects of the study medication, as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response in subjects with mild to moderate Alzheimer's disease.

Inclusion Criteria:

• Age 50 to 90
• Diagnosed with probable Alzheimer's disease
• 6 months of ongoing treatment for Alzheimer's (Namenda excluded)
• Stable dose of acetylcholinesterase inhibitor medication for 2 months
• Has a caregiver who is willing to attend all visits and oversee the patients compliance and report on the patients status

Exclusion Criteria:

• Diagnosis of vascular dementia
• History or evidence of any other CNS disorder (stroke, hemorrhage, epilepsy, Parkinson's, etc.)
• History of Type I Diabetes
• Type II Diabetes treated with insulin
• History of a cardiovascular event within the last 6 months
• History of psychiatric illness such as schizophrenia or bipolar affective disorder
• History or presence of gastro-intestinal, hepatic, or renal disease
• History of a bone marrow transplant
• Pregnant or lactating women
• History of drug or alcohol abuse

If you qualify, all study related care is provided at no charge including:

• Study visits and study related procedures/tests
• Laboratory tests
• Investigational drug
• Possible reimbursement for time and travel

Inclusion/Exclusion Criteria Must Be Met